ARMP.US Armata Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
3.87 USD
Close of Nov 14, 2026
2.75 14.98
Market cap
USD 144M
P/E
-
P/B
2.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARMP.US undervalued?

Graham number

The Graham number of Armata Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Armata Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Armata Pharmaceuticals Inc yet.

Armata Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Ph…

Full company profile